Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: AMA on NSAIDs

This article was originally published in The Tan Sheet

Executive Summary

AMA on NSAIDs: Consumers using OTC nonsteroidal anti-inflammatory drugs may be "placing themselves at risk for a catastrophic problem," including dyspepsia, mucosal lesions or ulcers, Michael Kimmey, MD, University of Washington, tells July 17 "media briefing" on pain held by the American Medical Association and sponsored by an Ortho-McNeil educational grant. According to Kimmey, 50% to 80% of people who go to hospitals for GI bleeding are taking NSAIDs. An AMA release notes that "there are other drugs for pain without gastrointestinal toxicity -- including acetaminophen." The Aspirin Foundation of America, in a same-day statement, argues that the program "appears to be one in a series of 'scientific' programs sponsored by Ortho-McNeil...which highlight purported adverse effects of analgesics that compete with Tylenol." The programs are an "important part" of the company's "marketing program for Tylenol," AFA maintains...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel